コロラド州における子宮内膜がんの臨床試験
コロラド州内の拠点で、子宮内膜がんに関する30件の研究が参加者を募集しています。
コロラド州内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- UCHealth University of Colorado Hospital, Aurora
- Poudre Valley Hospital, Fort Collins
- Cancer Care and Hematology-Fort Collins, Fort Collins
- 他2件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Rocky Mountain Cancer Center, Denver
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- UCHealth University of Colorado Hospital, Aurora
- UCHealth Memorial Hospital Central, Colorado Springs
- Memorial Hospital North, Colorado Springs
- 他5件
被験者募集中第3相
18歳以上 · 女性 · 2026/10/02更新 · NCT07198074A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- SCRI at HealthOne, Denver
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- UCHealth University of Colorado Hospital, Aurora
- AdventHealth Porter, Denver
被験者募集中第2相
18歳以上 · 女性 · 2026/09/24更新 · NCT05640999Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Colorado Cancer Center, Aurora
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- University of Colorado Cancer Center, Aurora
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- GSK Investigational Site, Aurora
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07213609ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Colorado, Aurora
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- SCRI at Denver Health, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06515613A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- SCRI at HCA Health One, Denver
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/27更新 · NCT07186842A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- SCRI Denver, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/27更新 · NCT07227168A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute (SCRI) at HealthONE-Denver, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/26更新 · NCT07383506Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital Colorado, Aurora
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Aurora
被験者募集中第1/2相
18歳〜130歳 · 全性別 · 2026/08/21更新 · NCT05797168A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- University of Colorado, Aurora
被験者募集中第2相
18歳以上 · 女性 · 2026/08/21更新 · NCT05548296A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University of Colorado, Aurora
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264A Study of PHST001 in Advanced Solid Tumors
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/12更新 · NCT06840886A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Rocky Mountain Cancer Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Rocky Mountain Cancer Center, Littleton
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/10更新 · NCT06695845First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- University of Colorado Cancer Center, Aurora
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/07更新 · NCT05768139Integrated Cancer Repository for Cancer Research
- Advent Health, Greenwood Village
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Sarah Cannon Research Institute at HealthONE, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/18更新 · NCT07503808Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Denver
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT06239194A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Denver
被験者募集中第1相
18歳以上 · 全性別 · 2026/01/07更新 · NCT06999187A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- University of Colorado Cancer Center, Aurora
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/04更新 · NCT05902988SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Aurora
- Massive Bio SYNERGY-AI site, Denver
- Massive Bio SYNERGY-AI site, Littleton
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE, Denver
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/02/13更新 · NCT05669430ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。